Search results | brain cancer

Reports

Brain Cancer Partnering

The Brain Cancer Partnering provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Trends analysis: Cancer vaccine partnering on the rise

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena.

Biotech All Stars Buy Castoff Experimental Merck Cancer Drug

Tesaro of Waltham, Mass., a tiny biotech now preparing for its initial public offering, just licensed a promising anti-cancer drug from Merck

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Merck & Schering Plough – Mega-merger that is greater than sum of its parts

Source: Datamonitor

Spectrum Pharmaceuticals: Where partnering IS the business model

Spectrum Pharmaceuticals is a biotechnology company providing key oncology and haematology products for patients around the world.

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Current Agreements Deal analysis Update : February 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in January 2013

M&A: Looking to be acquired in 2013?

M&A: Would you rather be smart or lucky?

Roche committed to innovation and growth

Roche will give an update on its strategy, which continues to be focused on medical innovation and sustainable growth. Through its leadership in personalised healthcare, Roche is uniquely positioned to develop therapies that advance current standards of care and improve people’s lives.

Memphis medical device company MRI Interventions goes public

Memphis based medical device company MRI Interventions officially launched its initial public offering this week

Events

Sorry, your search returned no results.


Deals

MDxHealth inks pharma partners deal with Merck KGaA for cancer Dx

MDxHealth  has inked a development and commercialization pharma partners deal with Merck KGaA, looking to market a companion diagnostic test for one of the drugmaker’s cancer treatments.

Big pharma, Baxter sells its vaccines for $635 million

Big pharma, Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer for a total cash consideration of $635 million, subject to certain adjustments.

Pfizer enters into a biotech licensing deal with Absorption Systems

Absorption Systems announces a biotech licensing agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems’ BCRP-MDCK cells.

Memphis medical device company MRI Interventions goes public

Memphis based medical device company MRI Interventions officially launched its initial public offering this week

Geron hires Stifel to sell stem cell assets, CEO says

Written by Ryan Flinn for Bloomberg. Geron Corp. hired Stifel Nicolaus & Co. to sell its embryonic stem cell therapy, the first approved in the U.S., as the company changes its focus to cancer drugs, Chief Executive Officer John Scarlett said.